Clinical Trials Sponsored by Octapharma

Total 94 results

Octapharma

Not yet recruiting

Phase 3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Acute Hereditary Angio Edema
Octapharma

Not yet recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Hemophilia A

Spain, France, Finland, Germany, Italy, Serbia
Octapharma

Recruiting

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

Acute Major Bleeding

United States, Bosnia and Herzegovina, Croatia, Spain, Georgia, Italy, Poland, Germany, Austria, Turkey, United Kingdom, Ukraine, France
Octapharma

Recruiting

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency

United States, Germany, Italy, Poland, Slovakia, Ukraine, Hungary
Octapharma

Recruiting

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Congenital Fibrinogen Deficiency

Germany
Octapharma

Active, not recruiting

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Von Willebrand Disease

United States, Moldova, Republic of, Czechia, Germany, North Macedonia, Russian Federation, Ukraine
Octapharma

Completed

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Von Willebrand Diseases

Lebanon, Croatia, United States, Belarus, Bulgaria, Hungary, Russian Federation, Ukraine
Octapharma

Completed

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

Reversal of Anticoagulant Treatment

United States
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Octapharma

Completed

Octaplas Pediatric Plasma Exchange Trial (Octaplas)

Adverse Effects in the Therapeutic Use of Plasma Substitutes

United States
Octapharma

Terminated

Octaplas Adult TTP Trial

Thrombotic Thrombocytopenic Purpura

United States
Octapharma

Completed

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Primary Immunodeficiency (PID)

France
Octapharma

Completed

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Congenital Fibrinogen Deficiency | Afibrinogenemia

Iran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
Octapharma

Completed

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

Austria, United Kingdom, Bulgaria, Hungary, Germany, Poland, Romania, Slovakia
Octapharma

Terminated

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States
Octapharma

Completed

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Primary Thrombocytopenia

Germany
Octapharma

Completed

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Immune Thrombocytopenic Purpura

Austria
Octapharma

Completed

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Octapharma

Not yet recruiting

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Acquired Antithrombin Deficiency
Octapharma

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Severe Hemophilia A

Spain, Croatia, Italy, North Macedonia, Serbia
Octapharma

Recruiting

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Pediatric Acute-Onset Neuropsychiatric Syndrome

United States, Sweden, Italy
Octapharma

Recruiting

Effectiveness and Tolerability of Eqwilate in Real-life Conditions

VWD - Von Willebrand's Disease

France
Octapharma

Recruiting

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients (Protect-NOW)

Haemophilia A

Belgium, Italy, United States, Azerbaijan, Belarus, Canada, Estonia, France, Germany, Hungary, Lithuania, Russian Federation, Spain, Turkey, United Kingdom, Mexico
Octapharma

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Chronic Immune Thrombocytopenia

United States
Octapharma

Completed

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Significant Bleeding Risk

Russian Federation, United States, Romania, Ukraine, Belarus, Bulgaria, Georgia, Germany, Moldova, Republic of, Poland, Spain
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Octapharma

Completed

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Secondary Immune Deficiency

France
Octapharma

Completed

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Hemophilia A

Norway, United States, France, United Kingdom, Italy, Czechia, Argentina, Belarus, Ecuador, Guatemala, Lithuania, Portugal, Slovakia
Octapharma

Completed

Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants

Emergency Care for Severe Bleeding While on Anticoagulants

France
Octapharma

Terminated

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Autoimmune Diseases

France, Martinique
Octapharma

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Severe Hemophilia A

Russian Federation, Ukraine
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Octapharma

Completed

Octaplas Pediatric Plasma Replacement Trial

Cardiac Surgery | Liver Dysfunction | Coagulopathy | Liver Surgery

United States
Octapharma

Completed

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Severe Hemophilia A

United States, Bulgaria
Octapharma

Completed

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder

Russian Federation
Octapharma

Completed

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Germany, Bulgaria
Octapharma

Completed

Octagam 5% Versus Comparator Post Marketing Trial

Primary Immune Deficiency Disorder

United States
Octapharma

Completed

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Primary Immunodeficiency

United Kingdom, Australia, Germany, Italy
Octapharma

Withdrawn

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency
Octapharma

Terminated

Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (POINT)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Octapharma

Completed

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (WONDERS)

Prevent Bleeding in Major Surgery

United States, Turkey, Romania, India, Bulgaria, Italy, Oman, Poland, South Africa
Octapharma

Completed

A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD

Comparison of Octaplas LG and Octaplas SD

Austria
Octapharma

Recruiting

Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery (FARES-2)

Bleeding Cardiac Surgery Patients

Canada, United States
Octapharma

Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy

United States
Octapharma

Recruiting

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Congenital Antithrombin Deficiency

Spain, United States, Italy, France, Hungary, Austria, Germany, United Kingdom
Octapharma

Recruiting

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Chronic Lymphocytic Leukemia | Hypogammaglobulinemia

United States, Denmark, Germany, Hungary, Italy, Poland, Russian Federation, Spain, Czechia, Greece, Israel, Turkey
Octapharma

Completed

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Covid-19

United States, Russian Federation, Ukraine
Octapharma

Completed

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Von Willebrand Diseases

Lebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria

3

Subscribe